ORION-9, a phase 3 randomized clinical trial, shows that inclisiran effectively reduces low-density lipoprotein cholesterol (LDL-C) by 50% at 18 months in patients with heterozygous familial hypercholesterolemia, according to results presented Monday at the American Heart Association Scientific Sessions 2019 in Philadelphia.